Cardiac magnetic resonance imaging and sudden death risk in patients with hypertrophic cardiomyopathy

Affiliations

¹ From the Institute of Cardiovascular Science, University College London, London, UK (W.J.M.); and Methodist DeBakey Heart and Vascular Center, Houston, TX (S.F.N.). william.mckenna@uclh.org.
² From the Institute of Cardiovascular Science, University College London, London, UK (W.J.M.); and Methodist DeBakey Heart and Vascular Center, Houston, TX (S.F.N.).

Editorial

William J McKenna et al. Circulation. 2014.

. 2014 Aug 5;130(6):455-7.

doi: 10.1161/CIRCULATIONAHA.114.010977.

¹ From the Institute of Cardiovascular Science, University College London, London, UK (W.J.M.); and Methodist DeBakey Heart and Vascular Center, Houston, TX (S.F.N.). william.mckenna@uclh.org.
² From the Institute of Cardiovascular Science, University College London, London, UK (W.J.M.); and Methodist DeBakey Heart and Vascular Center, Houston, TX (S.F.N.).

No abstract available

Keywords: Editorials; cardiomyopathy, hypertrophic; death, sudden, cardiac; magnetic resonance imaging.

Comment on

Prognostic value of quantitative contrast-enhanced cardiovascular magnetic resonance for the evaluation of sudden death risk in patients with hypertrophic cardiomyopathy.
Chan RH, Maron BJ, Olivotto I, Pencina MJ, Assenza GE, Haas T, Lesser JR, Gruner C, Crean AM, Rakowski H, Udelson JE, Rowin E, Lombardi M, Cecchi F, Tomberli B, Spirito P, Formisano F, Biagini E, Rapezzi C, De Cecco CN, Autore C, Cook EF, Hong SN, Gibson CM, Manning WJ, Appelbaum E, Maron MS. Chan RH, et al. Circulation. 2014 Aug 5;130(6):484-95. doi: 10.1161/CIRCULATIONAHA.113.007094. Circulation. 2014. PMID: 25092278 Clinical Trial.